Press releases

Press releases and press packs are intended to journalists, investors and shareholders. 

Paris, France,  November 30, 2007

Sanofi-aventis and Astellas to restructure the joint venture activities in Japan of Fujisawa sanofi-aventis K.K.

Sanofi-aventis and Astellas Pharma Inc. (hereinafter: “Astellas”, Headquarters: Tokyo, Japan, President and CEO: Masafumi Nogimori) announced today that they have agreed to restructure their joint venture activities in Japan (Fujisawa sanofi-aventis K.K., hereinafter: “FSA”). This operation, that will simplify the operational management, will be made in several steps and the process is expected to be completed substantially on December 31, 2007.

Established in 1982, FSA is a joint venture company 51% owned by sanofi-aventis and 49% by Astellas. FSA owns the rights to manufacture and sell certain products originating from sanofi-aventis such as Myslee® (zolpidem), Dogmatyl® (sulpiride), Primperan® (metoclopramide) and Gramalil® (tiapride).

In the restructuring, sanofi-aventis K.K., the Japanese subsidiary of sanofi-aventis, shall obtain certain rights to Myslee®. Myslee®, the leading treatment of insomnia, will continue to be co-promoted by sanofi-aventis K.K. and Astellas and distributed by Astellas. The other products, namely Primperan®, Dogmatyl® and Gramalil® will solely be marketed and distributed by Astellas.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-looking statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although ‘sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

• Download the press release dated November 30, 2007 (new window, PDF, 0.2 MB)